stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) Operating cash flow
IDEAYA Biosciences, Inc.'s operating cash flow for fiscal 2025 was −$71.1M, compared with −$247.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$347.4M. Over the past ten years it has ranged from −$247.6M (fiscal 2024) to $55.5M (fiscal 2020); the current reading is higher than 44% of that period. IDEAYA Biosciences, Inc. ranks 579th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$71.1M | — |
| FY2024 | −$247.6M | — |
| FY2023 | −$115.2M | — |
| FY2022 | −$87.2M | — |
| FY2021 | −$55.8M | — |
| FY2020 | $55.5M | — |
| FY2019 | −$39.3M | — |
| FY2018 | −$27.6M | — |
| FY2017 | −$12.2M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$93.5M | — |
| Jun 2026 | −$88.2M | — |
| Mar 2026 | −$75.2M | — |
| Dec 2025 | −$90.5M | — |
| 31 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | $51.9M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $49.9M |
| ELVN Enliven Therapeutics, Inc. compare | −$66.9M |
| CELC Celcuity, Inc. compare | −$191.7M |
| VRDN Viridian Therapeutics, Inc. compare | −$341.5M |
| IDYA IDEAYA Biosciences, Inc. | −$347.4M |
| BEAM Beam Therapeutics Inc. compare | −$388.6M |
| DNLI Denali Therapeutics Inc. compare | −$444.2M |
| DYN Dyne Therapeutics, Inc. compare | −$477.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement